Europe — EMA
Ipertrofan (Mepartricin)
GNH USA supplies Ipertrofan (Mepartricin), a macrolide antibiotic for chronic prostatitis and chronic pelvic pain syndrome. Request a quote for global supply.
Request sourcing
What is Mepartricin?
Mepartricin, the active ingredient in Ipertrofan, is a macrolide antibiotic presented as an oral tablet for oral use. It treats chronic prostatitis and chronic pelvic pain syndrome in adult males.
GNH USA supplies Ipertrofan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Mepartricin used for?
Mepartricin is used in the urological therapeutic area to manage chronic inflammatory conditions of the prostate.
- Chronic prostatitis: reduces prostatic inflammation and alleviates urinary symptoms. - Chronic pelvic pain syndrome: improves pelvic discomfort associated with prostatitis. - Prostatic infection: supports treatment of bacterial prostatitis by targeting pathogenic bacteria.
What are the side effects of Mepartricin?
Adverse reactions may occur with Mepartricin therapy.
Common Side Effects: - Nausea - Abdominal discomfort - Diarrhea - Headache - Dizziness - Altered taste perception
Serious or Rare Side Effects: - Anaphylactic reaction - Elevated liver enzymes - Neutropenia - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac arrhythmias (QT prolongation) - Clostridioides difficile‑associated colitis
What precautions apply to Mepartricin?
Before initiating Mepartricin, consider the following safety measures.
- Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown; assess potential infant exposure. - Renal impairment: monitor renal function and adjust if necessary. - Hepatic impairment: periodic liver‑function tests are recommended. - Drug interactions: review concomitant medications for potential interactions. - Store at below 25°C: keep in the original pack, protect from moisture.
What does Mepartricin interact with?
Mepartricin may interact with several drug classes; awareness helps prevent adverse outcomes.
Major Interactions (Avoid): - QT‑prolonging agents: increased risk of cardiac arrhythmia. - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): may raise Mepartricin plasma levels. - Anticoagulants (warfarin): potential enhancement of anticoagulant effect. - Live vaccines: possible reduction in vaccine efficacy. - Teratogenic drugs: avoid concurrent use during pregnancy.
Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Diuretics: monitor electrolytes for imbalance. - NSAIDs: increased risk of gastrointestinal irritation. - Probenecid: may alter renal excretion of Mepartricin. - Oral contraceptives: monitor for possible reduced effectiveness.



